Recommended immunization schedules: Canadian Immunization Guide
For health professionals
Notice
This chapter has not yet been updated with the following statements from the National Advisory Committee on Immunization (NACI):
- March 11, 2024: Recommendations for public health programs on the use of pneumococcal vaccines in children, including the use of 15-valent and 20-valent conjugate vaccines
- March 21, 2023: Interim guidance on the use of pneumococcal 15-valent conjugate vaccine (PNEU-C-15) in pediatric populations
- February 24, 2023: Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines.
This CIG chapter has not been updated to contain any information regarding COVID-19 vaccines, refer to the COVID-19 vaccine chapter.
Last partial content update (see Table of Updates): July 2023
Clarifications were made to Table 5 to better align with information provided in Part 4 chapters.
Last complete chapter revision: December 2013
On this page
- General recommendations
- Table 1: Routine childhood immunization schedule, infants and children (birth to 17 years of age)
- Table 2: Recommended immunization schedule, children (less than 7 years of age), NOT Previously Immunized as Infants
- Table 3: Recommended immunization schedule, children (7 to 17 years of age), NOT Previously Immunized
- Table 4: Additional recommended immunizations, children (birth to 17 years of age), Considered AT RISK due to Underlying Medical Conditions
- Table 5: Recommended immunization schedule, adults (18 years of age and older), NOT Previously Immunized
- Table 6: Recommended immunizations, adults (18 years of age and older), Previously Immunized
- Table 7: Additional recommended immunizations, adults (18 years of age and older), Considered at risk
General recommendations
Administration of vaccines in accordance with the immunization schedules summarized in the following tables will provide optimal protection from vaccine preventable diseases for most individuals. However, modifications of the recommended schedule may be necessary due to missed appointments or illness. In general, interruption of an immunization series does not require restarting the vaccine series, regardless of the interval between doses. Individuals with interrupted immunization schedules should be vaccinated to complete the appropriate schedule for their current age. Refer to Timing of vaccine administration in Part 1 and vaccine-specific chapters in Part 4 for additional information.
Similar, but not identical, vaccines may be available from different manufacturers; therefore, it is useful to review the relevant vaccine-specific chapters in the Canadian Immunization Guide as well as the manufacturer's product leaflet or product monograph before administering a vaccine. Refer to Principles of vaccine interchangeability in Part 1 for information about the interchangeability of similar vaccines from different manufacturers. Product monographs are periodically updated; it is a best practice to consult the information contained within the product monographs available through Health Canada's Drug Product Database.
Table 1: Routine childhood immunization schedule, infants and children (birth to 17 years of age)
- For children at-risk due to underlying medical conditions, refer to Table 4 for additional recommendations for immunization.
- [ ] = dose(s) may not be required depending upon age of child or vaccine used or both (refer to the relevant vaccine-specific chapter in Part 4 and provincial/territorial schedule). mos = months. yrs = years. P/T = provincial and territorial.
- Refer to Timing of vaccine administration and Vaccine administration practices in Part 1 regarding administration of multiple injections.
- Refer to vaccine-specific chapters in Part 4 for additional information.
VaccineFootnote * | Age | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Birth | 2 mos | 4 mos | 6 mos | 12 mos | 15 mos | 18 mos | 23 mos | 2 years | 4 years | 5 years | 6 years | 9 years | 12 years | 14 years | 15 years | 16 years | 17 years | |
DTaP-IPV-Hib or DTaP-HB-IPV-Hib |
- | Table 1 - Footnote A or Table 1 - Footnote B 1st dose |
Table 1 - Footnote A or Table 1 - Footnote B 2nd dose |
Table 1 - Footnote A or Table 1 - Footnote B 3rd dose |
Table 1 - Footnote A or 4th dose Generally at 18 months of age |
- | - | - | - | - | - | - | - | - | - | |||
DTaP-IPV or Tdap-IPV |
- | - | - | - | - | - | - | - | - | Table 1 - Footnote C | - | - | - | - | - | - | ||
Tdap | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Table 1 - Footnote D | - | ||
Rot | - | Table 1 - Footnote E 2 or 3 doses Complete series before 8 months |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
Pneu-C-13 | - | Table 1 - Footnote F | Table 1 - Footnote F | - | - | - | - | - | - | - | - | - | - | - | - | |||
Men-C-C | - | Table 1 - Footnote [G] According to P/T schedule |
Table 1 - Footnote G Generally at 12 months |
- | - | - | - | - | - | - | - | |||||||
Men-C-C or Men-C-ACYW |
- | - | - | - | - | - | - | - | - | - | - | - | - | Table 1 - Footnote H | - | - | - | - |
MMR and Var | - | - | - | - | Table 1 - Footnote I + Table 1 - Footnote J | Table 1 - Footnote I + Table 1 - Footnote J | - | - | - | - | - | - | ||||||
OR | ||||||||||||||||||
MMRV | - | - | - | - | Table 1 - Footnote K | Table 1 - Footnote K Generally at 4-6 years |
- | - | - | - | - | - | ||||||
HB | Table 1 - Footnote L 3 doses |
- | - | - | - | - | - | - | - | - | - | - | - | - | ||||
OR | ||||||||||||||||||
HB | - | - | - | - | - | - | - | - | - | - | - | - | Table 1 - Footnote M 2 or 3 doses |
|||||
HPV | - | - | - | - | - | - | - | - | - | - | - | - | Table 1 - Footnote N 2 or 3 doses |
- | - | - | ||
OR | ||||||||||||||||||
HPV | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Table 1 - Footnote O 3 doses |
||
Inf | - | - | - | Table 1 - Footnote P 1 or 2 doses Recommended annually |
Table 1 - Footnote P 1 dose Recommended annually |
|||||||||||||
Table 2: Recommended Immunization Schedule, Children (less than 7 years of age), NOT Previously Immunized as Infants
- For children at-risk due to underlying medical conditions, refer to Table 4 for additional recommendations for immunization.
- [ ] = dose(s) may not be required depending upon age of child or vaccine used or both (refer to the relevant vaccine-specific chapter in Part 4 and provincial/territorial schedule). mos = months.
- Refer to Timing of vaccine administration and Vaccine administration practices in Part 1 regarding administration of multiple injections.
- Refer to vaccine-specific chapters in Part 4 for additional information.
VaccineFootnote * | First visit | Time after first visit | 6-12 mos after last dose |
||||
---|---|---|---|---|---|---|---|
4 weeks | 8 weeks | 3 mos | 4 mos | 6 mos | |||
DTaP-IPV-Hib or DTaP-IPV |
Footnote A | - | Footnote A | - | Footnote A | - | Footnote A Footnote [B] |
Pneu-C-13 | Footnote [C] | - | Footnote [C] | - | - | - | - |
Men-C-C | Footnote D | - | - | - | - | - | - |
MMR | Footnote E | Footnote E | - | - | - | - | - |
Var | Footnote F | - | - | Footnote F | - | - | - |
OR | |||||||
MMRV | Footnote G | - | - | Footnote G | - | - | - |
HB | Footnote [H] | Footnote [H] | - | - | - | Footnote [H] | - |
Inf | Footnote I | Footnote I | - | - | - | - | - |
Table 3: Recommended immunization schedule, children (7 to 17 years of age), not previously immunized
- For children at-risk due to underlying medical conditions, refer to Table 4 for additional recommendations for immunization.
- [ ] = dose(s) may not be required depending upon age of child or vaccine used or both (refer to the relevant vaccine-specific chapter in Part 4 and provincial/territorial schedule). mos = months. yrs = years.
- Refer to Timing of vaccine administration and Vaccine administration practices in Part 1 regarding administration of multiple injections.
- Refer to the vaccine-specific chapters in Part 4 for additional information.
VaccineTable 3 Footnote * | First visit | Time after first visit | 6-12 mos after last dose | 10 yrs after last dose | |||
---|---|---|---|---|---|---|---|
4 weeks | 8 weeks | 3 mos | 6 mos | ||||
Tdap-IPV Tdap |
Table 3 Footnote A | - | Table 3 Footnote A | - | Table 3 Footnote A | Table 3 Footnote B | |
Men-C-C | Table 3 Footnote [C] 7-11 years of age |
- | - | - | - | - | - |
OR | |||||||
Men-C-C or Men-C-ACYW |
Table 3 Footnote D 12-17 years of age |
- | - | - | - | - | - |
MMR | Table 3 Footnote E | Table 3 Footnote E | - | - | - | - | - |
Var | Table 3 Footnote F | - | - | Table 3 Footnote F | - | - | - |
OR | |||||||
MMRV | Table 3 Footnote G 7-12 years of age |
- | - | Table 3 Footnote G | - | - | - |
HB | Table 3 Footnote H | Table 3 Footnote [H] | - | - | Table 3 Footnote H | - | - |
HPV | Table 3 Footnote I 9-14 years of age |
- | - | - | Table 3 Footnote I | - | - |
OR | |||||||
HPV | Table 3 Footnote I 9-14 years of age 3 doses |
- | - | ||||
OR | |||||||
HPV | Table 3 Footnote J 15-17 years of age 3 doses |
- | - | ||||
Inf | Table 3 Footnote K 7-8 years of age |
Table 3 Footnote K | - | - | - | - | - |
OR | |||||||
Inf | Table 3 Footnote K 9-17 years of age |
- | - | - | - | - | - |
|
Table 4: Additional recommended immunizations, children (birth to 17 years of age), considered at risk due to underlying medical conditions
- [ ] = dose(s) may not be required depending upon age of child or vaccine used or both (refer to vaccine-specific chapter in Part 4 and provincial/territorial schedule). mos = months. yrs = years.
- Refer to Immunization of travellers and Immunization of workers in Part 3 for additional information about vaccines recommended for travellers and workers.
- Refer to Immunization of immunocompromised persons and Immunization of persons with chronic diseases in Part 3 for additional condition-specific recommendations.
- Refer to Timing of vaccine administration and Vaccine administration practices in Part 1 regarding administration of multiple injections.
- Refer to the vaccine-specific chapters in Part 4 for additional information
VaccineFootnote * | Age | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Birth | 2 mos | 6 mos | 12 mos | 15 mos | 18 mos | 23 mos | 2 years | 3 years | 5-8 yrs | 9-17 yrs | |
Hib | - | - | - | - | - | - | - | - | - | Footnote A 1 dose |
|
Pneu-P-23 | - | - | - | - | - | - | - | Footnote B 1 dose + 1 booster dose if at highest risk |
|||
Pneu-C-13 | - | - | Footnote C | - | - | - | - | - | Footnote [C] If not previously received |
||
Men-C-ACYW | - | Footnote D 2, 3 or 4 doses + additional booster doses |
- | ||||||||
4CMenB | - | Footnote E 2, 3 or 4 doses + additional booster doses |
|||||||||
HA | - | - | - | Footnote F 2 doses |
|||||||
HB | Footnote G 3 or 4 doses |
||||||||||
Inf | - | - | Footnote H 1 or 2 doses Recommended annually |
Footnote H 1 dose Recommended annually |
|||||||
Table 5: Recommended immunization schedule, adults (18 years of age and older), not previously immunized
- For adults considered at-risk, refer to Table 7 for additional recommendations for immunization.
- [ ] = dose(s) may not be required depending upon age of vaccinee or vaccine used or both (refer to vaccine-specific chapter in Part 4 and provincial/territorial schedule). mos = months.
- Refer to Immunization of travellers and Immunization of workers in Part 3 for additional information about vaccines recommended for travellers and workers.
- Refer to Timing of vaccine vdministration and Vaccine vdministration practices in Part 1 regarding administration of multiple injections.
- Refer to vaccine-specific chapters in Part 4 for further information.
VaccineFootnote * | First visit | Time after First visit | 6-12 mos after last dose | 10 years after last dose | |||
---|---|---|---|---|---|---|---|
4 weeks | 6 weeks | 8 weeks | 6 mos | ||||
Tdap-IPV Tdap Td IPV |
Footnote A | - | - | Footnote A | - | Footnote A | Footnote B |
MMR | Footnote C | - | - | - | - | - | - |
Var | Footnote D 18-49 years of age |
- | Footnote D | - | - | - | - |
OR | |||||||
RZV | Footnote E 50 years of age and over |
- | - | Footnote E | - | - | - |
Pneu-P-23 | Footnote F | - | - | - | - | - | - |
Men-C-C or Men-C-ACYW |
Footnote G 18-24 years of age |
- | - | - | - | - | - |
HPV | Footnote H 3 doses |
- | - | ||||
Inf | Footnote I Annually |
||||||
Table 6: Recommended immunizations, adults (18 years of age and older), previously immunized
- For adults considered at-risk, refer to Table 7 for additional recommendations for immunization.
- [] = dose may not be required.
- Refer to Immunization of travellers and Immunization of workers in Part 3 for additional information about vaccines recommended for travellers and workers.
- Refer to Timing of vaccine administration and Vaccine administration practices in Part 1 regarding administration of multiple injections.
- Refer to vaccine-specific chapters in Part 4 for additional information.
VaccineFootnote * | Age | ||||
---|---|---|---|---|---|
18-26 years | 27-49 years | 50-59 years | 60 years | 65 years and older | |
Td | Footnote A 1 dose every 10 years |
||||
Tdap | Footnote B 1 dose |
||||
Pneu-P-23 | - | - | - | - | Footnote C 1 dose |
RZV | - | - | Footnote D 2 doses |
||
Inf | Footnote E Annually |
||||
Table 7: Additional recommended immunizations, adults (18 years of age and older), considered at risk
- Refer to Immunization of travellers and Immunization of workers in Part 3 for information about vaccines recommended for travellers and workers.
- Refer to Immunization of immunocompromised persons and Immunization of persons with chronic diseases in Part 3 for additional condition-specific immunization recommendations.
- Refer to Timing of vaccine administration and Vaccine administration practices in Part 1 regarding administration of multiple injections.
- Refer to vaccine-specific chapters in Part 4 for additional information.
VaccineFootnote * | Age |
---|---|
18 years of age and older | |
Hib | Footnote A 1 dose |
IPV | Footnote B 1 booster dose |
MMR | Footnote C Second dose |
Pneu-C-13 | Footnote D 1 dose |
Pneu-P-23 | Footnote E 1 dose + 1 booster dose if at highest risk |
Men-C-ACYW | Footnote F 2 doses + booster doses |
4CMenB | Footnote G 2 doses |
HA | Footnote H 2 doses |
HB | Footnote I 3 or 4 doses |
OR | |
HAHB | Footnote J 3 or 4 doses |
Inf | Footnote K Annually |
Typh-I | Footnote L 1 dose + booster doses if at ongoing risk |
OR | |
Typh-O | Footnote L 4 doses + booster doses if at ongoing risk |
Rab | Footnote M 3 doses + booster doses if required |
Var | Footnote N 2 doses |
Page details
- Date modified: